EBMT 2019 | Molecular techniques for monitoring MRD in AML
Torsten Haferlach
Torsten Haferlach, MD Munich Leukemia Laboratory, Munich, Germany, evaluates the different methods currently being used to monitor measurable residual disease (MRD) in acute myeloid leukemia (AML) patients. This video was recorder at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
Related videos
2:06
Uproleselan update: moving forward for R/R AML
Daniel DeAngelo
1:43
Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results
David Steensma
3:03
Mutant p53 re-activator APR-246 in MDS/AML
David Sallman
1:48
Genomic landscape of childhood ALL: new analysis delves deeper than ever
Charles Mullighan
4:40
ALL at ASH: four key updates
Marina Konopleva
